Your browser doesn't support javascript.
loading
Balancing benefits and limitations of linear energy transfer optimization in carbon ion radiotherapy for large sacral chordomas.
Parrella, Giovanni; Magro, Giuseppe; Chalaszczyk, Agnieszka; Rotondi, Marco; Ciocca, Mario; Glimelius, Lars; Fiore, Maria R; Paganelli, Chiara; Orlandi, Ester; Molinelli, Silvia; Baroni, Guido.
Afiliação
  • Parrella G; Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via G.Ponzio 34/5, 20133 Milan, Italy.
  • Magro G; Medical Physics Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
  • Chalaszczyk A; Radiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
  • Rotondi M; Raysearch Laboratories, Eugeniavägen 18, 113 68 Stockholm, Sweden.
  • Ciocca M; Medical Physics Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
  • Glimelius L; Raysearch Laboratories, Eugeniavägen 18, 113 68 Stockholm, Sweden.
  • Fiore MR; Radiotherapy Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
  • Paganelli C; Department of Electronics, Information and Bioengineering, Politecnico di Milano, Via G.Ponzio 34/5, 20133 Milan, Italy.
  • Orlandi E; Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Via A. Brambilla 74, 27100 Pavia, Italy.
  • Molinelli S; Clinical Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
  • Baroni G; Medical Physics Unit, National Center of Oncological Hadrontherapy (CNAO), Strada Campeggi, 53, 11 27100 Pavia, Italy.
Phys Imaging Radiat Oncol ; 31: 100624, 2024 Jul.
Article em En | MEDLINE | ID: mdl-39206357
ABSTRACT
Background and

Purpose:

A low linear energy transfer (LET) in the target can reduce the effectiveness of carbon ion radiotherapy (CIRT). This study aimed at exploring benefits and limitations of LET optimization for large sacral chordomas (SC) undergoing CIRT. Materials and

Methods:

Seventeen cases were used to tune LET-based optimization, and seven to independently test interfraction plan robustness. For each patient, a reference plan was optimized on biologically-weighted dose cost functions. For the first group, 7 LET-optimized plans were obtained by increasing the gross tumor volume (GTV) minimum LETd (minLETd) in the range 37-55 keV/µm, in steps of 3 keV/µm. The optimal LET-optimized plan (LETOPT) was the one maximizing LETd, while adhering to clinical acceptability criteria. Reference and LETOPT plans were compared through dose and LETd metrics (D x , L x to x% volume) for the GTV, clinical target volume (CTV), and organs at risk (OARs). The 7 held-out cases were optimized setting minLETd to the average GTV L98% of the investigation cohort. Both reference and LETOPT plans were recalculated on re-evaluation CTs and compared.

Results:

GTV L98% increased from (31.8 ± 2.5)keV/µm to (47.6 ± 3.1)keV/µm on the LETOPT plans, while the fraction of GTV receiving over 50 keV/µm increased on average by 36% (p < 0.001), without affecting target coverage goals, or impacting LETd and dose to OARs. The interfraction analysis showed no significant worsening with minLETd set to 48 keV/µm.

Conclusion:

LETd optimization for large SC could boost the LETd in the GTV without significantly compromising plan quality, potentially improving the therapeutic effects of CIRT for large radioresistant tumors.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article